Anti-MuSK Antibody-positive Myasthenia Gravis Mimicking Amyotrophic Lateral Sclerosis. 2015

Natsumi Furuta, and Kunihiko Ishizawa, and Makoto Shibata, and Setsuki Tsukagoshi, and Shun Nagamine, and Kouki Makioka, and Yukio Fujita, and Masaki Ikeda, and Shunsuke Yoshimura, and Masakatsu Motomura, and Koichi Okamoto, and Yoshio Ikeda
Department of Neurology, Gunma University Graduate School of Medicine, Japan.

We herein investigated the clinical features of three patients with anti-muscle-specific tyrosine kinase (MuSK) antibody-positive myasthenia gravis (MG), which was initially difficult to distinguish from amyotrophic lateral sclerosis (ALS). The patients exhibited dropped head syndrome or dysphagia as initial symptoms. Although their clinical findings were compatible with the revised El Escorial Criteria for ALS, their progression appeared to be more rapid than that of ALS. Both the edrophonium and repetitive nerve stimulation tests yielded negative results, and diurnal fluctuation was not confirmed. The patients were ultimately diagnosed with anti-MuSK antibody-positive MG. We therefore recommend the measurement of anti-MuSK antibodies when encountering such cases.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011950 Receptors, Cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology. ACh Receptor,Acetylcholine Receptor,Acetylcholine Receptors,Cholinergic Receptor,Cholinergic Receptors,Cholinoceptive Sites,Cholinoceptor,Cholinoceptors,Receptors, Acetylcholine,ACh Receptors,Receptors, ACh,Receptor, ACh,Receptor, Acetylcholine,Receptor, Cholinergic,Sites, Cholinoceptive
D003680 Deglutition Disorders Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS. Dysphagia,Swallowing Disorders,Esophageal Dysphagia,Oropharyngeal Dysphagia,Deglutition Disorder,Disorders, Deglutition,Dysphagia, Esophageal,Dysphagia, Oropharyngeal,Swallowing Disorder
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Natsumi Furuta, and Kunihiko Ishizawa, and Makoto Shibata, and Setsuki Tsukagoshi, and Shun Nagamine, and Kouki Makioka, and Yukio Fujita, and Masaki Ikeda, and Shunsuke Yoshimura, and Masakatsu Motomura, and Koichi Okamoto, and Yoshio Ikeda
September 2011, Orvosi hetilap,
Natsumi Furuta, and Kunihiko Ishizawa, and Makoto Shibata, and Setsuki Tsukagoshi, and Shun Nagamine, and Kouki Makioka, and Yukio Fujita, and Masaki Ikeda, and Shunsuke Yoshimura, and Masakatsu Motomura, and Koichi Okamoto, and Yoshio Ikeda
February 2023, Acta neurologica Belgica,
Natsumi Furuta, and Kunihiko Ishizawa, and Makoto Shibata, and Setsuki Tsukagoshi, and Shun Nagamine, and Kouki Makioka, and Yukio Fujita, and Masaki Ikeda, and Shunsuke Yoshimura, and Masakatsu Motomura, and Koichi Okamoto, and Yoshio Ikeda
October 2010, The Journal of the Association of Physicians of India,
Natsumi Furuta, and Kunihiko Ishizawa, and Makoto Shibata, and Setsuki Tsukagoshi, and Shun Nagamine, and Kouki Makioka, and Yukio Fujita, and Masaki Ikeda, and Shunsuke Yoshimura, and Masakatsu Motomura, and Koichi Okamoto, and Yoshio Ikeda
May 2006, Journal of neurology,
Natsumi Furuta, and Kunihiko Ishizawa, and Makoto Shibata, and Setsuki Tsukagoshi, and Shun Nagamine, and Kouki Makioka, and Yukio Fujita, and Masaki Ikeda, and Shunsuke Yoshimura, and Masakatsu Motomura, and Koichi Okamoto, and Yoshio Ikeda
January 2024, Brain and nerve = Shinkei kenkyu no shinpo,
Natsumi Furuta, and Kunihiko Ishizawa, and Makoto Shibata, and Setsuki Tsukagoshi, and Shun Nagamine, and Kouki Makioka, and Yukio Fujita, and Masaki Ikeda, and Shunsuke Yoshimura, and Masakatsu Motomura, and Koichi Okamoto, and Yoshio Ikeda
June 2016, Neuromuscular disorders : NMD,
Natsumi Furuta, and Kunihiko Ishizawa, and Makoto Shibata, and Setsuki Tsukagoshi, and Shun Nagamine, and Kouki Makioka, and Yukio Fujita, and Masaki Ikeda, and Shunsuke Yoshimura, and Masakatsu Motomura, and Koichi Okamoto, and Yoshio Ikeda
April 2006, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Natsumi Furuta, and Kunihiko Ishizawa, and Makoto Shibata, and Setsuki Tsukagoshi, and Shun Nagamine, and Kouki Makioka, and Yukio Fujita, and Masaki Ikeda, and Shunsuke Yoshimura, and Masakatsu Motomura, and Koichi Okamoto, and Yoshio Ikeda
January 2006, Klinische Monatsblatter fur Augenheilkunde,
Natsumi Furuta, and Kunihiko Ishizawa, and Makoto Shibata, and Setsuki Tsukagoshi, and Shun Nagamine, and Kouki Makioka, and Yukio Fujita, and Masaki Ikeda, and Shunsuke Yoshimura, and Masakatsu Motomura, and Koichi Okamoto, and Yoshio Ikeda
July 2009, Rinsho shinkeigaku = Clinical neurology,
Natsumi Furuta, and Kunihiko Ishizawa, and Makoto Shibata, and Setsuki Tsukagoshi, and Shun Nagamine, and Kouki Makioka, and Yukio Fujita, and Masaki Ikeda, and Shunsuke Yoshimura, and Masakatsu Motomura, and Koichi Okamoto, and Yoshio Ikeda
July 2019, Clinical neurology and neurosurgery,
Copied contents to your clipboard!